Overview

Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma

Status:
Unknown status

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Sixth Affiliated Hospital, Sun Yat-sen University

Treatments:

Oxaliplatin